Idhifa

Active Ingredient(s): Enasidenib
FDA Approved: * August 1, 2017
Pharm Company: * CELGENE CORP
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Idhifa Overview

Enasidenib (INN; trade name Idhifa) is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test.[1] It is an inhibitor of IDH2. It was developed by Agios Pharmaceuticals and is licensed to Celgene for further development. Contents 1 Medical use 2 Adverse effects 3 Pharmacology 4 History 5 References Medical use Enasideni...

Read more Idhifa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Enasidenib

Recent Idhifa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Idhifa: (2 results)

Sorted by National Drug Code

• 59572-705 Idhifa 50 mg Oral Tablet, Film Coated by Celgene Corporation
• 59572-710 Idhifa 100 mg Oral Tablet, Film Coated by Celgene Corporation

Other drugs which contain Enasidenib or a similar ingredient: (1 result)

• ENASIDENIB